Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Background Despite recent advances in the treatment of advanced non-small-cell lung cancer,
there remains a need for effective treatments for progressive disease. We assessed the …
there remains a need for effective treatments for progressive disease. We assessed the …
[HTML][HTML] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
AT Shaw, DW Kim, K Nakagawa, T Seto… - … England Journal of …, 2013 - Mass Medical Soc
Background In single-group studies, chromosomal rearrangements of the anaplastic lymphoma
kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an …
kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an …
[HTML][HTML] First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Background The efficacy of the ALK inhibitor crizotinib as compared with standard
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer (NSCLC) …
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer (NSCLC) …
[HTML][HTML] AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer
Background The EGFR T790M mutation is the most common mechanism of drug resistance
to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have …
to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have …
Observation of Large Violation in the Neutral Meson System
We present a measurement of the standard model CP violation parameter sin 2 φ 1 based
on a 29.1 fb− 1 data sample collected at the ϒ (4 S) resonance with the Belle detector at the …
on a 29.1 fb− 1 data sample collected at the ϒ (4 S) resonance with the Belle detector at the …
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
…, TP Hughes, HM Kantarjian, DW Kim… - Blood, The Journal …, 2013 - ashpublications.org
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet …
inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet …
Virus-enabled synthesis and assembly of nanowires for lithium ion battery electrodes
The selection and assembly of materials are central issues in the development of smaller,
more flexible batteries. Cobalt oxide has shown excellent electrochemical cycling properties …
more flexible batteries. Cobalt oxide has shown excellent electrochemical cycling properties …
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Background Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in
patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of …
patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of …
[HTML][HTML] Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
…, AT Shaw, S Gadgeel, JS Ahn, DW Kim… - … England Journal of …, 2017 - Mass Medical Soc
Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …
[HTML][HTML] Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
G Saglio, DW Kim, S Issaragrisil… - … England Journal of …, 2010 - Mass Medical Soc
Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib.
We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients …
We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients …